Method for intravesical drug delivery
View Patent ↗Implant devices for intravesical administration and local drug delivery. The device has a body which includes a hollow tube formed of a biocompatible material; at least one reservoir in the tube which contains a drug; and one or more apertures through which the drug can be released. The device is configured for minimally invasive insertion into a body cavity, such as the bladder. The hollow tube may be elastomeric to permit the device to be elastically deformed from its initial shape into an elongated shape for passage through a catheter, where following such passage the device can return to or toward its initial shape to facilitate retention of the device in the body cavity. The body may have a narrow, elongated shape effective to permit insertion of the drug delivery device through a catheter without necessarily deforming the body, yet include flexible projections which effect retention within the body cavity.
1. A method for administering a drug to a patient, comprising:
providing a drug delivery device, the drug delivery device comprising a water-permeable wall that defines an interior reservoir, the interior reservoir housing a solid or semisolid drug formulation, which comprises a drug;
releasing the drug delivery device from a deployment lumen into a body cavity of the patient, whereupon exiting the deployment lumen the drug delivery device is changed from a first configuration suited for passage of the drug delivery device through the lumen to a second configuration suited for retaining the drug delivery device within the body cavity;
solubilizing the drug formulation with fluid that passes through the water-permeable wall into the interior reservoir; and
releasing solubilized drug from the drug delivery device into the body cavity,
wherein the method is carried out without an additional procedure to load a pharmaceutical into the drug delivery device after the drug delivery device is released into the body cavity.
2. The method of claim 1 , wherein the body cavity comprises the patient's bladder.
3. The method of claim 2 , wherein releasing the drug delivery device from a deployment lumen into the body cavity comprises:
inserting a catheter or cystoscope into the patient's urethra, the catheter or cystoscope comprising the deployment lumen; and
driving the drug delivery device from the deployment lumen into the bladder.
4. The method of claim 3 , further comprising removing the catheter or cystoscope from the patient's urethra after the drug delivery device is driven from the deployment lumen.
5. The method of claim 1 , wherein the drug formulation is in a solid form which is loaded into the interior reservoir before the drug delivery device is released from the deployment lumen.
6. The method of claim 1 , wherein:
the first configuration comprises an elongated shape for passage of the drug delivery device through the deployment lumen positioned in the urethra; and
the second configuration comprises an expanded shape for retention in the bladder.
7. The method of claim 6 , wherein the expanded shape comprises a coil.
8. The method of claim 1 , wherein releasing the drug from the drug delivery device comprises continuously releasing a therapeutically effective amount of the drug over a period that exceeds one day.
9. The method of claim 1 , wherein the drug is released from the drug delivery device through one or more apertures, the release being driven by diffusion or by osmotic pressure within the interior reservoir.
10. The method of claim 1 , wherein the wall comprises silicone.
11. The method of claim 1 , wherein the drug comprises lidocaine or another anesthetic agent.
12. The method of claim 1 , wherein the drug is selected from the group consisting of glycosaminoglycans, pentosan polysulfate, dimethyl sulfoxide, chondroitin sulfate C, oxybutynin, mitomycin C, and combinations thereof.
13. The method of claim 1 , further comprising removing the drug delivery device from the body cavity after the drug is released.
14. A method for locally administering a drug to a patient's bladder, comprising:
deploying a drug delivery device into the patient's bladder via a cystoscope or catheter inserted through the patient's urethra, wherein the drug delivery device comprises (i) a tube, and (ii) a solid or semisolid drug formulation, which comprises a drug, housed within the tube, wherein the drug delivery device has an initial expanded shape and is deformable into an elongated shape; and
releasing the drug from the drug delivery device into the bladder,
whereupon exiting the cystoscope or catheter into the bladder, the drug delivery device returns from the elongated shape, which permits passage of the drug delivery device through the cystoscope or catheter, into the initial expanded shape, which retains the drug delivery device in the bladder,
wherein the method is carried out without an additional procedure to load a pharmaceutical into the drug delivery device after the drug delivery device is released into the bladder.
15. The method of claim 14 , wherein releasing the drug comprises solubilizing the drug within the tube in vivo and then releasing the solubilized drug from the drug delivery device through one or more apertures in the tube.
16. The method of claim 15 , wherein the solubilized drug is driven through the one or more apertures by diffusion or by osmotic pressure within the tube.
17. The method of claim 14 , wherein the expanded shape comprises a coiled portion.
18. The method of claim 14 , wherein the tube comprises silicone or another elastomeric material.
19. The method of claim 14 , wherein the drug formulation is in a solid form which is loaded into the drug delivery device before the drug delivery device is deployed into the patient's bladder.
20. The method of claim 14 , wherein releasing the drug from the drug delivery device comprises continuously releasing a therapeutically effective amount of the drug over a period that exceeds one day.
21. The method of claim 14 , wherein the drug comprises lidocaine or another anesthetic agent.
22. The method of claim 14 , wherein the drug is selected from the group consisting of glycosaminoglycans, pentosan polysulfate, dimethyl sulfoxide, chondroitin sulfate C, oxybutynin, mitomycin C, and combinations thereof.
23. The method of claim 14 , wherein the drug is indicated for the patient for the treatment of interstitial cystitis, overactive bladder syndrome, or bladder cancer.
24. The method of claim 14 , wherein the drug formulation is in the form of at least one rod.
25. The method of claim 14 , wherein the drug formulation is in the form of a gel.
26. The method of claim 2 , wherein the solubilizing fluid comprises fluid from the patient's bladder.
27. A method for administering a drug to a bladder of a patient, the method comprising:
deforming a drug delivery device from an initial expanded shape to an elongated shape, the expanded shape adapted for retaining the device in the bladder and the elongated shape adapted for deploying the device from a deployment instrument positioned in a urethra of the patient;
releasing the drug delivery device from the deployment instrument into the bladder, whereupon exiting the deployment instrument the drug delivery device returns from the elongated shape to the initial expanded shape for retention in the bladder;
solubilizing a solid drug formulation within the drug delivery device with fluid that permeates through a water-permeable wall portion of the drug delivery device; and
releasing solubilized drug from the drug delivery device into the bladder,
wherein the method is carried out without an additional procedure to load a pharmaceutical into the drug delivery device after the drug delivery device is released into the bladder.
28. The method of claim 27 , wherein the solubilized drug comprises a local anesthetic agent.
29. The method of claim 27 , wherein the solubilized drug comprises lidocaine hydrochloride.
30. The method of claim 27 , wherein releasing solubilized drug comprises releasing the solubilized drug through an aperture in the device via diffusion, osmotic pressure, or a combination thereof.
31. The method of claim 27 , wherein the drug is released into the bladder for at least 24 hours.
32. A method for administering a drug to a bladder of a patient, the method comprising:
providing a drug delivery device having a housing which comprises an elastomeric tube having a central bore, which contains a drug;
deforming the drug delivery device from an initial shape to an elongated shape, the initial shape being effective to prevent voiding of the device from the bladder and the elongated shape effective to permit deploying the device from a deployment instrument positioned in a urethra of the patient;
releasing the drug delivery device from the deployment instrument into the bladder, whereupon exiting the deployment instrument the drug delivery device returns from the elongated shape to the initial shape; and
releasing the drug from the drug delivery device into the bladder wherein the method is carried out without an additional procedure to load a pharmaceutical into the drug delivery device after the drug delivery device is released into the bladder.
33. The method of claim 32 , wherein the drug comprises lidocaine hydrochloride.
34. The method of claim 32 , wherein the drug is released through at least one aperture in the elastomeric tube.
35. The method of claim 32 , wherein the drug is a solid form and the method further comprises solubilizing the drug with water that passes through a water-permeable wall of the elastomeric tube in vivo.